unanswered questions about the Redux (dexfenfluramine) and Pondimin (fenfluramine) withdrawal
October 1997
There are lots of unanswered questions about the Redux (dexfenfluramine) and Pondimin (fenfluramine) withdrawal.
Preliminary tests suggest that 30% of patients on Redux or Pondimin might have damaged heart valves. There are also concerns about pulmonary hypertension and possible neurotoxicity.
These problems might be due to too much serotonin.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote